Clinical utility of clodronate in the prevention and management of osteoporosis in patients intolerant of oral bisphosphonates

被引：15

作者：

Muratore, Maurizio ^{[1
]}

Quarta, Eugenio ^{[1
]}

Grimaldi, Antonella ^{[1
]}

Calcagnile, Fabio ^{[1
]}

Quarta, Laura ^{[1
]}

机构：

[1] Hosp Galateo, Dept Rheumatol, I-73016 San Cesario Di Lecce, Italy

来源：

DRUG DESIGN DEVELOPMENT AND THERAPY | 2011年 / 5卷

关键词：

clodronate; bisphosphonates; osteoporosis; bone turnover; menopause; tolerability; BONE-MINERAL DENSITY; POSTMENOPAUSAL OSTEOPOROSIS; DOUBLE-BLIND; RISK-FACTORS; INTRAVENOUS CLODRONATE; INFLAMMATORY ACTIONS; VERTEBRAL FRACTURES; HIP FRACTURE; OPEN-LABEL; WOMEN;

D O I：

10.2147/DDDT.S12139

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Bisphosphonates have a long history in the treatment of osteoporosis and bone-related disease. This review focuses on the use of a specific nonaminobisphosphonate, clodronate, which appears to be much better tolerated than other bisphosphonates and free of high-risk contraindications. Specifically, this paper reviews its use in the prevention of osteoporosis in postmenopausal women, taking into account its tolerability profile and recent safety issues arising regarding the use of bisphosphonates.

引用

页码：445 / 454

页数：10

共 50 条

[21] Oral bisphosphonates and incidence of cancers in patients with osteoporosis: a systematic review and meta-analysis
Yingfang Deng
Zhen Zhang
Xi Jia
Wenke Cheng
Xixi Zhou
Yi Liu
Miaozhou Wang
Archives of Osteoporosis, 2019, 14
[22] Acceptability and engagement amongst patients on oral and intravenous bisphosphonates for the treatment of osteoporosis in older adults
Narayanasamy, Melanie
Bishop, Simon
Sahota, Opinder
Paskins, Zoe
Gittoes, Neil
Langley, Tessa
AGE AND AGEING, 2022, 51 (11)
[23] Oral bisphosphonates and incidence of cancers in patients with osteoporosis: a systematic review and meta-analysis
Deng, Yingfang
Zhang, Zhen
Jia, Xi
Cheng, Wenke
Zhou, Xixi
Liu, Yi
Wang, Miaozhou
ARCHIVES OF OSTEOPOROSIS, 2018, 14 (01)
[24] Osteoporosis management and falls prevention in patients with haemophilia: Review of haemophilia guidelines
Petkovic, Madison J.
Tran, Huyen A.
Ebeling, Peter R.
Zengin, Ayse
HAEMOPHILIA, 2022, 28 (03) : 388 - 396
[25] Comparison of intravenous pamidronate to standard therapy for osteoporosis - Use in patients unable to take oral bisphosphonates
Miller, RG
Chretien, KC
Meoni, LA
Liu, YP
Klag, MJ
Levine, MA
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2005, 11 (01) : 2 - 7
[26] Oral bisphosphonates reduce the risk of clinical fractures in glucocorticoid-induced osteoporosis in clinical practice
T. Thomas
S. Horlait
J. D. Ringe
A. Abelson
D. T. Gold
P. Atlan
J. L. Lange
Osteoporosis International, 2013, 24 : 263 - 269
[27] The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis
Ebina, Kosuke
Hashimoto, Jun
Kashii, Masafumi
Hirao, Makoto
Kaneshiro, Shoichi
Noguchi, Takaaki
Tsukamoto, Yasunori
Yoshikawa, Hideki
JOURNAL OF BONE AND MINERAL METABOLISM, 2017, 35 (01) : 91 - 98
[28] Osteoporosis in Adult Patients with Intellectual and Developmental Disabilities: Special Considerations for Diagnosis, Prevention, and Management
Fritz, Rachel
Edwards, Linda
Jacob, Rafik
SOUTHERN MEDICAL JOURNAL, 2021, 114 (04) : 246 - 251
[29] Compliance and persistence with oral bisphosphonates for the treatment of osteoporosis in female patients with rheumatoid arthritis
Ji-Heh Park
Eun-Kyoung Park
Dong-Wan Koo
Shinwon Lee
Sun-Hee Lee
Geun-Tae Kim
Seung-Geun Lee
BMC Musculoskeletal Disorders, 18
[30] Indirect comparison of teriparatide, denosumab, and oral bisphosphonates for the prevention of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis
Zhang, Lanling
Pang, Yafei
Shi, Yeqing
Xu, Meijuan
Xu, Xia
Zhang, Ju
Ji, Lianmei
Zhao, Dongbao
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2015, 22 (09): : 1021 - 1025

← 1 2 3 4 5 →